Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $27.73: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 13.14; Below-average business quality.
Agios is a commercial-stage rare disease biopharma with two marketed products: PYRUKYND (mitapivat for PK deficiency in US/EU and thalassemia in Saudi Arabia) and AQVESME (mitapivat for thalassemia, US launched January 2026). PYRUKYND generated $54M in net product revenues in... Read more
Sell if holding. Engine safety override at $27.73: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 13.14; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 46. Score 5.1/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Agios Pharmaceuticals, Inc.
Latest news
- Agios Pharmaceuticals Submits Supplemental New Drug Application To FDA Seeking Accelerated Approval Of Oral Pyruvate Kin — benzinga May 12, 2026 positive
- Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $36 — benzinga Apr 30, 2026 positive
- Earnings Scheduled For April 29, 2026 — benzinga Apr 29, 2026 neutral
- Agios Pharmaceuticals Q1 EPS $(1.69) Beats $(1.79) Estimate, Sales $20.746M Beat $13.646M Estimate — benzinga Apr 29, 2026 positive
- B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $41 — benzinga Apr 21, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductmitapivat (PYRUKYND/AQVESME)10-K Item 1: 'The lead product candidate in our portfolio, mitapivat, is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $27.73: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 13.14; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 46. Prior stop was $25.83. Score 5.1/10, moderate confidence.
Take-profit target: $35.78 (+29.0% upside). Prior stop was $25.83. Stop-loss: $25.83.
Concentration risk — Product: mitapivat (PYRUKYND/AQVESME); Quality below floor (1.6 < 4.0).
Agios Pharmaceuticals, Inc. trades at a P/E of N/A (forward -6.1). TrendMatrix value score: 5.4/10. Verdict: Sell.
16 analysts cover AGIO with a consensus score of 4.1/5. Average price target: $41.
What does Agios Pharmaceuticals, Inc. do?Agios is a commercial-stage rare disease biopharma with two marketed products: PYRUKYND (mitapivat for PK deficiency in...
Agios is a commercial-stage rare disease biopharma with two marketed products: PYRUKYND (mitapivat for PK deficiency in US/EU and thalassemia in Saudi Arabia) and AQVESME (mitapivat for thalassemia, US launched January 2026). PYRUKYND generated $54M in net product revenues in 2025; the pipeline includes tebapivat (LR MDS/SCD), AG-181 (PKU), and AG-236 (PV).